The next blockbuster in queue..........

Rapamycin (sirolimus) derivative Everolimus (RAD-001) was developed and marketed by Novratis, Earlier the product was approved as immunosupressant under trade name Certican for rejection in heart transplantation and lately it was approved as an drug for treating kidney cancer and currently many researchers are considering the use of Everolimus and other mTOR inhibitors for different types of cancers...so wait for a new cancer blockbuster is not long :)